Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. cut its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 34.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,190 shares of the medical equipment provider’s stock after selling 9,126 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Hologic were worth $1,400,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after buying an additional 450,190 shares in the last quarter. Black Creek Investment Management Inc. raised its holdings in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after acquiring an additional 87,176 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HOLX. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Leerink Partners reduced their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Evercore ISI lifted their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Performance

Shares of HOLX opened at $77.54 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The business’s fifty day moving average price is $80.77 and its 200 day moving average price is $78.22. The stock has a market capitalization of $18.01 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.89 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.